These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Assaraf YG Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765 [TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of adaptation to folate deficiency. Ifergan I; Assaraf YG Vitam Horm; 2008; 79():99-143. PubMed ID: 18804693 [TBL] [Abstract][Full Text] [Related]
4. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465 [TBL] [Abstract][Full Text] [Related]
5. Folylpoly-γ-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer. Raz S; Stark M; Assaraf YG Drug Resist Updat; 2016 Sep; 28():43-64. PubMed ID: 27620954 [TBL] [Abstract][Full Text] [Related]
6. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Gonen N; Assaraf YG Drug Resist Updat; 2012 Aug; 15(4):183-210. PubMed ID: 22921318 [TBL] [Abstract][Full Text] [Related]
7. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626 [TBL] [Abstract][Full Text] [Related]
8. Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets. Assaraf YG; Ifergan I; Kadry WN; Pinter RY J Theor Biol; 2006 Jun; 240(4):637-47. PubMed ID: 16352313 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Sierra EE; Goldman ID Semin Oncol; 1999 Apr; 26(2 Suppl 6):11-23. PubMed ID: 10598550 [TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Fotoohi AK; Assaraf YG; Moshfegh A; Hashemi J; Jansen G; Peters GJ; Larsson C; Albertioni F Biochem Pharmacol; 2009 Apr; 77(8):1410-7. PubMed ID: 19426680 [TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of resistance to antifolates, a review. Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336 [TBL] [Abstract][Full Text] [Related]
12. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo. Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461 [TBL] [Abstract][Full Text] [Related]
13. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558 [TBL] [Abstract][Full Text] [Related]
14. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Zhao R; Babani S; Gao F; Liu L; Goldman ID Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762 [TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718 [TBL] [Abstract][Full Text] [Related]
16. Folate and antifolate pharmacology. Kamen B Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019 [TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance. Takemura Y; Kobayashi H; Miyachi H Int J Hematol; 1997 Dec; 66(4):459-77. PubMed ID: 9479873 [TBL] [Abstract][Full Text] [Related]
19. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier. Zhao R; Chattopadhyay S; Hanscom M; Goldman ID Clin Cancer Res; 2004 Dec; 10(24):8735-42. PubMed ID: 15623659 [TBL] [Abstract][Full Text] [Related]
20. Anticancer antifolates: current status and future directions. McGuire JJ Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]